B-cell targeted therapy with rituximab for thyroid eye disease: Closer to the clinic

Survey of Ophthalmology

Volumn 58, Issue 3, 2013, Pages 252-265

  Shen, Sunny ^a,b   Chan, Anita ^a,b,c   Sfikakis, Petros P ^d   Hsiu Ling, Andrea Low ^c   Detorakis, Efstathios T ^e   Boboridis, Kostas G ^e   Mavrikakis, Ioannis ^e  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e ATHENS MEDICAL CENTER   (Greece)

Author keywords

B cells; CD20; Immunopathogenesis; Rituximab; Thyroid eye disease

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; STEROID;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTHROPATHY; B LYMPHOCYTE; CHILL; COLITIS; CYTOKINE PRODUCTION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOCRINE OPHTHALMOPATHY; EPIDERMOLYSIS; FEVER; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPOTENSION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; LOW DRUG DOSE; NAUSEA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; RELAPSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULITIS; VIRUS REACTIVATION; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84876410485     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2012.10.006     Document Type: Review

References (66)

1. Bahn R.S. Graves' ophthalmopathy. N Engl J Med 2010, 362:726-738.
2. Bartalena L. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?. Clin Endocrinol (Oxf) 2010, 73:149-152.
3. Bartalena L., Baldeschi L., Dickinson A., et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008, 158:273-285.
4. Bartalena L., Baldeschi L., Dickinson A.J., et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008, 18:333-346.
5. Bonara P., Vannucchi G., Campi I., et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clin Rev Allergy Immunol 2008, 34:118-123.
6. Bradley E.A., Gower E.W., Bradley D.J., et al. Orbital radiation for Graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008, 115:398-409.
7. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
8. Clifford D.B., Ances B., Costello C., et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011, 68:1156-1164.
9. Cohen Y., Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab. Hematol J 2002, 3:61-62.
10. Douglas R.S., Naik V., Hwang C.J., et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008, 181:5768-5774.
11. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J Immunol 2004, 172:3422-3427.
12. Eckstein A.K., Plicht M., Lax H., et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006, 91:3464-3470.
13. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
14. El Fassi D., Banga J.P., Gilbert J.A., et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009, 130:252-258.
15. El Fassi D., Clemmensen O., Nielsen C.H., et al. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab 2007, 92:3762-3763.
16. El Fassi D., Nielsen C.H., Bonnema S.J., et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007, 92:1769-1772.
17. El Fassi D., Nielsen C.H., Hasselbalch H.C., et al. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006, 154:623-632.
18. El Fassi D., Nielsen C.H., Hasselbalch H.C., et al. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006, 16:709-710.
19. El Fassi D., Nielsen C.H., Junker P., et al. Systemic adverse events following rituximab therapy in patients with Graves' disease. J Endocrinol Invest 2011, 34:e163-e167.
20. El Fassi D., Nielsen C.H., Kjeldsen J., et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008, 57:714-715.
21. Ezeonyeji A.N., Isenberg D.A. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 2012, 51:476-481.
22. Gerding M.N., van der Meer J.W., Broenink M., et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000, 52:267-271.
23. Gopinath B., Musselman R., Adams C.L., et al. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features. Thyroid 2006, 16:967-974.
24. Hasselbalch H.C. B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett 2003, 88:85-86.
25. Heemstra K.A., Toes R.E., Sepers J., et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 2008, 159:609-615.
26. Heyes C., Nolan R., Leahy M., et al. Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. Australas J Dermatol 2012, 53:e1-e4.
27. Ho V.H., Chevez-Barrios P., Jorgensen J.L., et al. Receptor expression in orbital inflammatory syndromes and implications for targeted therapy. Tissue Antigens 2007, 70:105-109.
28. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
29. Katoh N., Matsuda M., Ishii W., et al. Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. Intern Med 2010, 49:237-241.
30. Khanna D., Chong K.K., Afifiyan N.F., et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010, 117:133-139.
31. Khoo D.H., Eng P.H., Ho S.C., et al. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 2000, 10:1093-1100.
32. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
33. Krassas G.E., Stafilidou A., Boboridis K.G. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin Endocrinol (Oxf) 2010, 72:853-855.
34. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985, 314:537-539.
35. Liossis S.N., Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008, 127:280-285.
36. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
37. Madaschi S., Rossini A., Formenti I., et al. Treatment of thyroid-associated orbitopathy with rituximab-a novel therapy for an old disease: case report and literature review. Endocr Pract 2010, 16:677-685.
38. Marcocci C., Bartalena L., Rocchi R., et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003, 88:3561-3566.
39. Merrill J.T., Neuwelt C.M., Wallace D.J., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
40. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 2005, 7(Suppl 3):S19-S25.
41. Mourits M.P., Prummel M.F., Wiersinga W.M., et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinl Endocrinol 1997, 47:9-14.
42. Mourits M.P., van Kempen-Harteveld M.L., Garcia M.B., et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000, 355:1505-1509.
43. Nielsen C.H., El Fassi D., Hasselbalch H.C., et al. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther 2007, 7:1061-1078.
44. Nielsen J.F., El Fassi D., Nielsen C.H., et al. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy. Acta Ophthalmol 2009, 87:927-929.
45. Pritchard J., Han R., Horst N., et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003, 170:6348-6354.
46. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
47. Salvi M., Pedrazzoni M., Girasole G., et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000, 143:197-202.
48. Salvi M., Vannucchi G., Campi I., Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction?. Orbit 2009, 28:251-255.
49. Salvi M., Vannucchi G., Campi I., et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007, 156:33-40.
50. Salvi M., Vannucchi G., Campi I., et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009, 131:360-365.
51. Salvi M., Vannucchi G., Campi I., et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006, 154:511-517.
52. Salvi M., Vannucchi G., Curro N., et al. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol 2012, 130:122-124.
53. Schafranski M.D. Idiopathic orbital inflammatory disease successfully treated with rituximab. Clin Rheumatol 2009, 28:225-226.
54. Sfikakis P.P., Boletis J.N., Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005, 17:550-557.
55. Silkiss R.Z., Reier A., Coleman M., et al. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 2010, 26:310-314.
56. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
57. Smith T.J., Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004, 89:5076-5080.
58. Starkey K.J., Janezic A., Jones G., et al. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 2003, 30:369-380.
59. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
60. Vallerskog T., Gunnarsson I., Widhe M., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74.
61. Valyasevi R.W., Erickson D.Z., Harteneck D.A., et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999, 84:2557-2562.
62. Vannucchi G., Campi I., Bonomi M., et al. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 2010, 161:436-443.
63. Wakelkamp I.M., Bakker O., Baldeschi L., et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol 2003, 58:280-287.
64. Wiersinga W.M. Management of Graves' ophthalmopathy. Nature clinical practice. Endocrinol Metabol 2007, 3:396-404.
65. Zaja F., Baccarani M., Mazza P., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
66. Zang S., Ponto K.A., Kahaly G.J. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011, 96:320-332.